CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 44 enrolled
Drug / intervention
PTH(1-84) +3 moredrug
Likely dose
PTH(1-84) 1.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00683163
NCT00683163Phase 3Completed
CompareCT.gov

PTH & Ibandronate Combination Study (PICS): Optimizing the Use of PTH With Boniva (Pilot Randomized Controlled Trial)

University of California, San Francisco·interventional·Posted May 23, 2008·Updated Nov 5, 2013

In Brief

A Phase 3 clinical trial evaluating PTH(1-84), Ibandronate, and 2 other interventions for Osteoporosis. Completed, enrolled 44 participants across 1 site.

Detailed Summary

This study will test in several innovative ways, several different combinations of PTH and oral monthly ibandronate for the treatment of osteoporosis in postmenopausal women. The intension is to provide other options for treatment than the current standard 2 year course of drug therapy. These options may lead to treatment where the two years of therapy are spread over several years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 23, 2008
Enrollment StartMay 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.1 years ago

Interventions

PTH(1-84)drug

1.4 mg injected subcutaneously (in the abdomen) daily

Ibandronatedrug

150mg by mouth once monthly

Placebo injectionother

Daily injections as placebo for PTS 1-84

Placebo pillsother

Monthly pills as placebo for oral ibandronate